Sage Journals: Discover world-class research

Abstract

Keywords

cancer diabetes insulin glargine insulin therapy neutral protamine Hagedorn insulin

References

Hemkens

Grouven

Bender

Günster

Gutschmidt

Selke

Sawicki

. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52 (9): 1732–44.

Gale

. Insulin glargine and cancer: another side to the story? Lancet. 2009;374 (9689): 521.

Pocock

Smeeth

. Insulin glargine and malignancy: an unwarranted alarm. Lancet. 2009;374 (9689): 511–3.

Home

Lagarenne

. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia. 2009;52 (12): 2499–506.

Rosenstock

Fonseca

McGill

Riddle

Hallé

Hramiak

Johnston

Davis

. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia. 2009;52 (9): 1971–3.

Garg

Hirsch

Skyler

. Insulin glargine and cancer—an unsubstantiated allegation. Diabetes Technol Ther. 2009;11 (8): 473–6.

Insulin Glargine and Incidence of Cancer—An Ongoing Debate

Abstract

Keywords

References